Factors Affecting Voriconazole Trough Concentration and Optimal Maintenance Voriconazole Dose in Chinese Children

Yi-Chang Zhao1,2, Yang Zou3, Jing-Jing Hou1,2

  • 1The Second Xiangya Hospital, Central South University, Changsha 410011, China.

Insights

Optimizing voriconazole dosage in children is crucial. This study found that weight, dose, bilirubin, urea nitrogen, and CYP2C19 phenotypes influence voriconazole levels, suggesting personalized dosing strategies for pediatric patients.

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Clinical Pharmacy

Background:

  • Voriconazole is a key antifungal for invasive aspergillosis (IA).
  • Limited data exists on voriconazole use and optimal dosing in pediatric populations.
  • Therapeutic drug monitoring (TDM) is essential for optimizing antifungal therapy.

Purpose of the Study:

  • To explore maintenance voriconazole doses for optimizing pediatric dosage.
  • To identify factors influencing voriconazole trough concentrations in children.
  • To improve treatment outcomes for invasive aspergillosis in pediatric patients.

Main Methods:

  • A retrospective, non-interventional clinical study.
  • Inclusion of 94 pediatric patients with 145 voriconazole trough concentrations.
  • Multivariate analysis to identify influencing factors on drug concentration.

Main Results:

  • Therapeutic drug monitoring-guided adjustments increased the probability of achieving target voriconazole concentrations (1.0-5.5 µg/mL) from 45.3% to 53.8%.
  • Optimal maintenance doses varied by age group, with lower doses generally required compared to drug label recommendations.
  • Weight, dose before sampling, direct bilirubin, urea nitrogen, and CYP2C19 phenotypes significantly influenced voriconazole trough concentrations.

Conclusions:

  • Pediatric voriconazole maintenance doses may require adjustment below label recommendations, necessitating further research.
  • Key factors influencing voriconazole concentration in Chinese children include age, weight, dose, direct bilirubin, urea nitrogen, and CYP2C19 phenotypes.
  • Personalized dosing strategies considering these factors are recommended for effective voriconazole therapy in children.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
15
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
20
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
12
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
24
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
14
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.6K